Condition: Type 1 Diabetes Mellitus · Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
The goal is to establish the effect of oral inulin supplementation on continuous glucose monitoring (CGM) metrics and immunological parameters in adults with type 1 diabetes. The investigators will perform a double-blind, randomized, placebo-controlled trial in 2x38 participants to measure effects on CGM metrics, gut microbiome composition, residual beta cell and immunological parameters.
This description comes directly from the study's public registry record.
Nordin Hanssen, Principal Investigator · +31 20-5669111 · n.m.j.hanssen@amsterdamumc.nl
Always discuss trial participation with your own doctor first.
| Diabeter Centrum Amsterdam | Amsterdam, Netherlands | Recruiting |
| Amsterdam UMC | Amsterdam, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07050888